Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nemonoxacin - TaiGen Biotechnology

Drug Profile

Nemonoxacin - TaiGen Biotechnology

Alternative Names: Nemonoxacin malate sodium chloride; Taigexyn; TG-873870

Latest Information Update: 28 May 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Procter & Gamble
  • Developer R-Pharm; TaiGen Biotechnology; Zhejiang Medicine
  • Class Antibacterials; Piperidines; Quinolones; Small molecules
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Community-acquired pneumonia
  • Phase II Diabetic foot ulcer
  • Phase Unknown Skin and soft tissue infections
  • No development reported Kidney disorders

Most Recent Events

  • 28 May 2020 No recent reports of development identified for phase-I development in Kidney-disorders(In the elderly, In adults) in China (PO, Capsule)
  • 16 Oct 2019 Preregistration for Community-acquired pneumonia in Taiwan (IV)
  • 05 Feb 2018 The Chinese FDA grants priority review to nemonoxacin for Community-acquired pneumonia
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top